Preclinical safety and efficacy of a new recombinant FIX drug product for treatment of hemophilia B

Baxter has developed a new recombinant factor IX (rFIX) drug product (BAX326) for treating patients with hemophilia B, or congenital FIX deficiency. An extensive preclinical program evaluated the pharmacokinetics, efficacy, and safety of BAX326 in different species. The efficacy of BAX326 was tested...

Descripción completa

Detalles Bibliográficos
Autores principales: Dietrich, Barbara, Schiviz, Alexandra, Hoellriegl, Werner, Horling, Frank, Benamara, Karima, Rottensteiner, Hanspeter, Turecek, Peter L., Schwarz, Hans Peter, Scheiflinger, Friedrich, Muchitsch, Eva-Maria
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Japan 2013
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7091414/
https://www.ncbi.nlm.nih.gov/pubmed/24061775
http://dx.doi.org/10.1007/s12185-013-1448-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7091414/
https://www.ncbi.nlm.nih.gov/pubmed/24061775
http://dx.doi.org/10.1007/s12185-013-1448-z

Ejemplares similares